LUNAI BIOWORKS INC
LNAINASDAQ🏆 #5046 by market capUS Equity
$1.75▼ $0.08 (−4.37%)
After hours · at closeTrack LNAI
Get earnings, price moves & breaking news on Telegram
24h▼ 4.4%
7d▼ 22.2%
14d▼ 19.0%
30d▼ 27.1%
ytd▼ 75.3%
1y▼ 82.9%
🏦Market Cap
$8M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
-360.7%
Thin
💵FCF Margin
-25114.9%
Thin
⚖️P/S Ratio
417.8x
Expensive
Otter Score
44
Weak
Trading Snapshot
- Day Range
- $1.72 – $1.77
- 52-Week Range
- $1.21 – $13.28
- Volume
- $2.98B
- Avg Volume
- $3.50B
- Shares Outstanding
- 4.5M
- Next Earnings
- Dec 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $20,942
- Last Q Revenue
- $20,942
- P/E Ratio
- -0.0
- P/S Ratio
- 417.8x
- EPS (TTM)
- $-41.06
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +45.1%
Why Investors Own LNAI
- ✓High-growth profile — revenue up +5.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LUNAI BIOWORKS INC
LNAIFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$19M▼ −77.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$8M▼ −28.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.9M▲ +45.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$2M▲ +$4M YoY
StockOtter · stockotter.spaceAbout LUNAI BIOWORKS INC
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100
Analyst Price Target
ⓘAverage Target
$2.20
▲ +25.7% Upside
High Target$2.63
Low Target$1.68
Based on 19 analysts
Latest News & Updates
🚀
CNBC·2h ago
LUNAI BIOWORKS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift LNAI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
LUNAI BIOWORKS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.